(127 days)
The BE CERTAIN™ Home Pregnancy Test is intended for the qualitative identification of the elevated level of Human Chorionic Gonadotrophin (hCG) in urine to aid in the determination of pregnancy. It is for over-the-counter consumer use.
The BE CERTAIN™ Home Pregnancy Test is an hCG assay, comprising of a rapid one-step test, based on an immunochromatographic technology. The test is made up of a membrane with an absorbent pad overlapping a strip of fiber glass paper that is impregnated with a lyophilized colloidal conjugate of gold particles and monoclonal solid phase antibodies to hCG. Other absorbent pads at the end of the assay absorb excess sample fluid. The urine sample is introduced into the device and proceeds through the absorbent pad, then laterally onto a chromatographic membrane. As it contacts the membrane, the sample dissolves the lyophilized conjugate. In a reactive sample, the hCG antigen will attach to the antibodies in the colloidal solution. As the conjugate moves forward on the membrane, anti-hCG monoclonal antibody affixed on the test zone ("T") will bind the hCG-gold conjugate complex, forming a pink line ("T"). All samples will cause a pink colored line to appear in the control zone ("C"). This line is formed by the binding of the polyclonal antibodies (Anti-mouse IgG) affixed onto the control zone to the sample-colloidal gold conjugate. Presence of this line indicates that the test has been carried out correctly. In less than 5 minutes, levels of hCG as low as 25mlU/ml can be detected.
Here's a breakdown of the acceptance criteria and the study that proves the device meets them, based on the provided text:
Acceptance Criteria and Device Performance for BE CERTAIN™ Home Pregnancy Test
The BE CERTAIN™ Home Pregnancy Test is intended for the qualitative identification of Human Chorionic Gonadotrophin (hCG) in urine to aid in the determination of pregnancy for over-the-counter consumer use.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria Category | Specific Acceptance Criterion | Reported Device Performance (BE CERTAIN™ Home Pregnancy Test) |
|---|---|---|
| Sensitivity/Detection Limit | Detect hCG levels as low as 25 mIU/ml with 95% positivity. | 25 mIU/ml: 5 out of 5 samples (100%) tested positive. 50 mIU/ml: 5 out of 5 samples (100%) tested positive. 100 mIU/ml: 5 out of 5 samples (100%) tested positive. The sponsor claims a detection limit of 25 mIU/ml. |
| Specificity | No false positives with physiological concentrations of hLH, hFSH, and hTSH. No interference from hLH, hFSH, and hTSH when hCG is present (leading to false negatives). | hLH (100, 300, 500 mIU/ml), hFSH (100, 300, 500 mIU/ml), hTSH (750, 1000, 1250 µIU/ml): All 0 of 5 samples (0%) tested positive without hCG. hLH, hFSH, hTSH + 10 mIU/ml hCG: All 0 of 5 samples (0%) tested positive (indicating no false positives even at sub-detection limit hCG levels). hLH, hFSH, hTSH + 50 mIU/ml hCG: All 5 of 5 samples (100%) tested positive (indicating accurate detection of hCG in the presence of these hormones). |
| Interference by Exogenous Compounds | No interference from specified prescription/OTC drugs, chemical analytes, biological analytes. | All tested analytes (Acetaminophen, Aspirin, Ampicillin, Tetracycline, Caffeine, Ascorbic Acid, Glucose, Protein, Albumin, Bilirubin, Hemoglobin, Triglyceride at specified concentrations): 0 of 3 samples (0%) tested positive without hCG, and 3 of 3 samples (100%) tested positive with 50 mIU/ml hCG. No interference observed. |
| pH Interference | No adverse effect on test performance with urine pH ranging from 3 to 10. | pH 3, 5, 7, 10: 0 of 1 samples (0%) tested positive without hCG, and 1 of 1 samples (100%) tested positive with 50 mIU/ml hCG. Human urine samples with pH ranges between 3-10 did not adversely affect the test and produced the expected results. |
| User Performance (End User vs. Professional User) - Dip Method | Strong concordance (high sensitivity and specificity) between results obtained by end-users and professional users, both using the dip method. | Concordance: 100/100 = 100% (95% CI: 96% - 100%). Sensitivity: 61/61 = 100% (95% CI: 94% - 100%). Specificity: 39/39 = 100% (95% CI: 91% - 100%). |
| Comparison to Predicate Device (End User vs. Predicate) | Strong concordance (high sensitivity and specificity) between results obtained by end-users (BE CERTAIN™) and the predicate device (E.P.T.®) used by professional users. | Concordance: 99/100 = 99% (95% CI: 95% - 100%). Sensitivity: 61/62 = 98.3% (95% CI: 91% - 100%). Specificity: 38/38 = 100% (95% CI: 91% - 100%). |
| User Performance (End User - Dropstream Method vs. Predicate - Dip Method) | Equivalent results when BE CERTAIN™ is used with a urine dropstream method compared to the predicate device using a dip method. | Concordance: 50/50 = 100% (95% CI: 93% - 100%). Sensitivity: 27/27 = 100% (95% CI: 88% - 100%). Specificity: 23/23 = 100% (95% CI: 86% - 100%). |
2. Sample Size Used for the Test Set and Data Provenance
- Sensitivity/Detection Limit:
- Sample Size: 30 human urine samples from different non-pregnant male or female subjects (used as a base for spiking). For each hCG concentration, 5 samples were tested.
- Data Provenance: Not explicitly stated, but implies laboratory-prepared samples using human urine, therefore likely prospective/controlled.
- Specificity (LH, FSH, TSH):
- Sample Size: 45 human urine samples from different normal, non-pregnant females. For each hormone concentration/condition, 5 samples were tested.
- Data Provenance: Not explicitly stated, but implies laboratory-prepared samples using human urine, therefore likely prospective/controlled.
- Interfering Substances:
- Sample Size: Human urine samples from non-pregnant female or male subjects. For each analyte/condition, 3 samples were tested.
- Data Provenance: Not explicitly stated, but implies laboratory-prepared samples using human urine, therefore likely prospective/controlled.
- pH Interference:
- Sample Size: Human urine samples. For each pH level, 1 sample was tested.
- Data Provenance: Not explicitly stated, but implies laboratory-prepared samples using human urine, therefore likely prospective/controlled.
- Clinical Performance (Dip Method):
- Sample Size: 100 spiked human urine samples from normal, non-pregnant females.
- Data Provenance: Not explicitly stated, but "spiked human urine samples" suggests controlled laboratory setting, thus prospective. Country of origin not specified.
- Clinical Performance (Urine Dropstream Method):
- Sample Size: 50 spiked human urine samples from normal, non-pregnant females.
- Data Provenance: Not explicitly stated, but "spiked human urine samples" suggests controlled laboratory setting, thus prospective. Country of origin not specified.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
- For the non-clinical (sensitivity, specificity, interference) studies: The "ground truth" was established by the precise spiking of hCG and other hormones/substances into known negative urine samples. This is a deterministic ground truth based on measurable concentrations, not expert interpretation.
- For the clinical performance studies:
- There was a "professional user" who tested the BE CERTAIN™ device using the dip method and the E.P.T.® Pregnancy Test (predicate device).
- The qualifications of this "professional user" are not specified.
- The "ground truth" for these comparative studies was essentially the results of the professional user's application of the predicate device or the subject device itself, not an independent, higher-level ground truth like pathology. The comparison itself forms the "truth" for concordance purposes.
4. Adjudication Method for the Test Set
- There is no explicit mention of an adjudication method in the context of resolving discrepancies for any of the studies. All results are presented as direct counts of positives/negatives based on the test's outcome.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
- No, a typical MRMC comparative effectiveness study was not explicitly conducted as described for AI devices assessing complex medical images.
- However, comparative studies were performed:
- The BE CERTAIN™ test results by an "End User" were compared to the BE CERTAIN™ test results by a "Professional User" (Table 5). This can be seen as comparing two "readers" (end-user vs. professional) on the same "cases" (spiked urine samples).
- The BE CERTAIN™ test results by an "End User" were compared to the E.P.T.® Pregnancy Test results by a "Professional User" (Table 6 and Table 7). This compares one device used by one type of reader against another device used by another type of reader.
- Effect size of human readers improvement with AI vs without AI assistance: This is not applicable, as this is a diagnostic test kit, not an AI assistance tool for human readers interpreting data. The studies focused on device performance and user equivalence.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- This is not applicable in the classical sense for an "algorithm only" device. The BE CERTAIN™ Home Pregnancy Test is an in-vitro diagnostic device that requires human interaction to perform the test and interpret the visual result (presence or absence of colored lines).
- However, the non-clinical studies (sensitivity, specificity, interference) can be considered "standalone" in the sense that they evaluated the chemical and immunological performance of the device without direct consideration of "end-user" variability in interpretation, focusing on the inherent capability of the test strip itself under controlled conditions. The "professional user" studies also represent a controlled, expert application of the device.
7. The Type of Ground Truth Used
- Non-clinical studies (Sensitivity, Specificity, Interference): Quantitative spiking of hCG and other substances into known negative urine samples. This is a manufactured or controlled standard ground truth based on known concentrations.
- Clinical performance (Comparison studies): The "ground truth" was established by comparing the results of the BE CERTAIN™ Home Pregnancy Test (either by end-user or professional user) against:
- The results of the BE CERTAIN™ Home Pregnancy Test performed by a professional user (seen as a reference for the device's intended performance).
- The results of the legally marketed predicate device (E.P.T.® Pregnancy Test) performed by a professional user.
- Therefore, the ground truth here is largely a comparative reference standard based on an already cleared device and/or expert application of the new device.
8. The Sample Size for the Training Set
- This device is an immunochromatographic test kit, not an algorithm that undergoes a "training phase" with a training set of data in the typical machine learning sense. There is no explicit mention of a "training set" for the device itself.
- The development process would involve R&D and optimization, but not "training data" in the AI context.
9. How the Ground Truth for the Training Set Was Established
- As there is no "training set" in the context of an algorithm, this question is not applicable. The development of the device would have relied on established biochemical principles and experimental validation during its design phase.
{0}------------------------------------------------
510(k) SUMMARY (As Required by IV. Section 807.92(c)
NOV 2 3 2005
OWNER'S NAME [807.92(a)(1)] (A)
| Owner's Name: | Victor J. SantosPresident |
|---|---|
| Company: | Natureplex, LLC |
| Address: | 3791 Airpark StreetMemphis, TN 38118 |
| Phone: | (866) 323-0107 |
| FAX: | (901) 323-2088 |
| Contact Person: | Victor J. Santos |
| Date Prepared: | September 15, 2005 |
NAME OF THE DEVICE [807.92(a)(2)] (B)
BE CERTAINTM Home Pregnancy Test Trade Name: hCG Pregnancy Test Common Name: Classification Name: FDA Product Code: LCX Kit. Test. Pregnancy, hCG, Over-the-Counter
LEGALLY MARKETED DEVICE [807.92(a)(3)] (C)
Substantial equivalence is being claimed with the following legally marketed device: E.P.T. Pregnancy Test (K# 033658).
DESCRIPTION OF THE DEVICE [807.92(a)(4)] (D)
The BE CERTAIN™ Home Pregnancy Test is an hCG assay, comprising of a rapid one-step test, based on an immunochromatographic technology. The test is made up of a membrane with an absorbent pad overlapping a strip of fiber glass paper that is impregnated with a lyophilized colloidal conjugate of gold particles and monoclonal solid phase antibodies to hCG. Other absorbent pads at the end of the assay absorb excess sample fluid. The urine sample is introduced into the device and proceeds through the absorbent pad, then laterally onto a chromatographic membrane. As it contacts the membrane, the sample dissolves the lyophilized conjugate. In a reactive sample, the hCG antigen will attach to the antibodies in the colloidal solution. As the conjugate moves forward on the membrane, anti-hCG monoclonal antibody affixed on the test zone ("T") will bind the hCG-gold conjugate complex, forming a pink line ("T"). All samples will cause a pink colored line to appear in the control zone ("C"). This line is formed by the binding of the polyclonal antibodies (Anti-mouse IgG) affixed onto the control zone to the sample-colloidal gold conjugate. Presence of this line indicates that the test has been carried out correctly. In less than 5 minutes, levels of hCG as low as 25mlU/ml can be detected.
{1}------------------------------------------------
INTENDED USE OF THE DEVICE [807.92(a)(5)] (E)
The BE CERTAIN™ Home Pregnancy Test is intended for the qualitative identification of the elevated level of Human Chorionic Gonadotrophin (hCG) in urine to aid in the determination of pregnancy. It is for over-the-counter consumer use.
TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE AS (F) COMPARED TO PREDICATE DEVICE [807.92(a)(5)]
The BE CERTAIN™ Home Pregnancy Test is substantially equivalent to the E.P.T. 8 Pregnancy Test [#K033658] based on the following characteristics:
| ITEM | BE CERTAIN™ HomePregnancy Test | E.P.T.® Pregnancy Test |
|---|---|---|
| Intended Use | Qualitative identification ofpregnancy hormone i.e.,Human ChorionicGonadotrophin (hCG) | Qualitative identification ofpregnancy hormone i.e.,Human ChorionicGonadotrophin (hCG) |
| Indications for Use | Determination of pregnancy | Determination of pregnancy |
| Target Population | Pregnant women | Pregnant women |
| Where Used | Home | Home |
| Formats Available | Casette | Casette |
| Sterility | Non-sterile | Non-sterile |
| Specimen Type | Human urine | Human urine |
| Antibodies | • Polyclonal anti-mouse IgG• Anti-β-hCG antibody andanti-α hCG monoclonalantibody | • Polyclonal anti-mouse IgG• Anti-β-hCG antibody andanti-α hCG monoclonalantibody |
| Cutoff | 25 mIU/ml | 25 mIU/ml |
| Storage Temperature | 4 – 30° C | 2 – 30° C |
| Read Time | 3 – 5 Minutes | 2 – 10 Minutes |
NON-CLINICAL PERFORMANCE DATA [807.92(b)(1)] AND (G) CONCLUSIONS FROM NON-CLINICAL TESTS [807.92(b)(3)]
SENSITIVITY/DETECTION LIMIT DATA (1)
To determine the sensitivity/detection limit of the BE CERTAIN™ Home Pregnancy Test, the analyte concentration of Human Chorionic Gonadotrophin (hCG) at which 95% of the test results are positive was determined. This was carried out by spiking human urine samples from 30 different non-pregnant male or female subjects with different concentrations of hCG. A total of five different samples at each concentration of hCG was blindly labeled and tested with the BE CERTAIN™ Home Pregnancy Test. The results of this study are presented in Table 1 below.
{2}------------------------------------------------
| hCG CONCENTRATION | POSITIVE | NEGATIVE |
|---|---|---|
| 0 mIU/ml | 0 of 5 | 5 of 5 |
| 12.5 mIU/ml | 1 of 5 | 4 of 5 |
| 18.75 mIU/ml | 3 of 5 | 2 of 5 |
| 25 mIU/ml | 5 of 5 | 0 of 5 |
| 50 mIU/ml | 5 of 5 | 0 of 5 |
| 100 mIU/ml | 5 of 5 | 0 of 5 |
Sensitivity/Detection Limit Data for the BE CERTAIN™ Home Pregnancy Table 1.
The sensitivity of the BE CERTAIN™ Home Pregnancy Test was tested by spiking thirty negative urine samples with varying concentrations of hCG. None of the samples (0%) for 0 mIU/ml of hCG had tested positive. Conversely, 1 out of 5 (20%) and 3 out of 5 (60%) for 12.5 mIU/ml and 18.75 mIU/ml of hCG, respectively, had tested positive. All (0070) for 12:5 mIU/ml, 50 mIU/ml, and 100 mIU/ml, and 100 mIU/ml had tested positive with the Samples (100%) 10125 Pregnancy Test. The sponsor claims a detection limit of 25 mIUml for the BE CERTAIN™ Home Pregnancy Test.
SPECIFICITY DATA INCLUDING LH, FSH, AND TSH (2)
To determine the specificity of the BE CERTAIN™ Home Pregnancy Test, in terms of its To determine the specifiery of concentration of Human Luteinizing Hornone Closs-Teach ity with mga physioisg - comone (hFSH), and Human Thyroid Stimulating (Incri), Trainan Fromers Samples from a total of 45 different normal, normal, normal, non-pregnant fromous (ITCPT), mailing with varying concentration of hLH, hFSH, and hTSH, with or without hCG. The results of this study are presented in Table 2 below.
| Table 2. Specificity Data for the BE CERTAIN™ Home Pregnancy Test. | |||||||
|---|---|---|---|---|---|---|---|
| HORMONES | 5 mls URINE | 5 mls URINE +10 mIU/ml hCG | 5 mls URINE +50 mIU/ml hCG | ||||
| (+) | (-) | (+) | (-) | (+) | (-) | ||
| hLH | 100 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 |
| 300 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 | |
| 500 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 | |
| hFSH | 100 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 |
| 300 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 | |
| 500 mIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 | |
| hTSH | 750 µIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 |
| 1,000 µIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 | |
| 1,250 µIU/ml | 0 of 5 | 5 of 5 | 0 of 5 | 5 of 5 | 5 of 5 | 0 of 5 |
Specificity Data for the BE CERTAIN™ Home Pregnancy Test. THIA 2
For the human urine samples spiked with hLH, hFSH, and hTSH at varying concentrations, none of the samples (0%) showed a positive reading with the BE
{3}------------------------------------------------
CERTAIN™ Home Pregnancy Test. Similarly, for the human urine + 10 mIU/ml hCG samples that were spiked with hLH, hFSH, and hTSH at varying concentrations, none of the samples (0%) showed a positive reading with the BE CERTAIN™ Home Pregnancy Test. Conversely, for the human urine + 50 mIU/ml hCG samples that were spiked with hLH, hFSH, and hTSH at varying concentrations, all samples (100%) showed a positive reading with the BE CERTAIN™ Home Pregnancy Test as would have been expected since the BE CERTAIN™ Home Pregnancy Test has been demonstrated to have a detection limit of hCG at 25 mIU/ml.
INTERFERING SUBSTANCES DATA (3)
To determine the interference by certain exogenous compounds, human urine samples from non-pregnant female or male subjects were spiked with prescription/OTC drugs. chemical analytes, biological analytes, as well as titrated for pH, and tested with the BE CERTAIN™ Home Pregnancy Test. The results of the analyte interfering study are presented in Table 3 below.
| ANALYTES | 5 mls URINE | 5 mls URINE + 50 mIU/ml hCG | ||
|---|---|---|---|---|
| (+) | (-) | (+) | (-) | |
| Acetaminophen (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Aspirin (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Ampicillin (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Tetracycline (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Caffeine (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Ascorbic Acid (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Glucose (2000 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Protein (2000 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Albumin (20 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Bilirubin (2 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Hemoglobin (1 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
| Triglyceride (800 mg/dL) | 0 of 3 | 3 of 3 | 3 of 3 | 0 of 3 |
Table 3: Analyte Interfering Data for the BE CERTAIN™ Pregnancy Test.
The results of the pH interfering study are presented in Table 4 below.
| Table 4:pH | pH Interfering Data for the BE CERTAIN™ Pregnancy Test.5 mls URINE | 5 mls URINE +50 mIU/ml hCG | ||
|---|---|---|---|---|
| (+) | (-) | (+) | (-) | |
| pH 3 | 0 of 1 | 1 of 1 | 1 of 1 | 0 of 1 |
| pH 5 | 0 of 1 | 1 of 1 | 1 of 1 | 0 of 1 |
| pH 7 | 0 of 1 | 1 of 1 | 1 of 1 | 0 of 1 |
| pH 10 | 0 of 1 | 1 of 1 | 1 of 1 | 0 of 1 |
{4}------------------------------------------------
No interference was observed by the exogenous compounds tested above, as observed in this study using the BE CERTAIN™ Home Pregnancy Test. Further, human urine samples with pH ranges between 3-10 did not adversely affect the test and produced the expected results.
CLINICAL PERFORMANCE DATA [807.92(b)(2)] AND (H) CONCLUSIONS FROM CLINICAL TESTS [807.92(b)(3)]
COMPARISON STUDY USING THE DIP METHOD (1)
Spiked human urine samples from 100 normal, non-pregnant females were tested in order to determine the correlation of the new test, the BE CERTAIN™ Pregnancy Test, when used by subjects using a dip method, with that of the BE CERTAIN™ Pregnancy Test, when tested by a professional user, as well as with that of a reference standard, the E.P.T. Pregnancy Test (i.e., the predicate device; previously cleared under 510(k) #K033658) The results of this study are as follows:
Table 5. Concordance of BE CERTAIN™ Home Pregnancy Test (Tested by End User) Compared with BE CERTAIN™ Home Pregnancy Test (Tested by Professional User), Both Following a Urine Dip Method.
| BE CERTAIN™ (Prof. User) | ||||
|---|---|---|---|---|
| (+) | (-) | |||
| BE CERTAIN™(End User) | (+) | 61 | 0 | 61 |
| (-) | 0 | 39 | 39 | |
| Total | 61 | 39 | 100 |
Based on the above 2x2 analysis, the Concordance of the BE CERTAIN™ Home Pregnancy Test when tested by the End User and the Professional User is 100/100= 100%, with a 95% confidence interval of 96% - 100%. The sensitivity of the BE CERTAIN™ Home Pregnancy Test is 61/61= 100%, with a 95% confidence interval of 94% - 100%. Finally, the Specificity of the BE CERTAIN™ Home Pregnancy Test is 39/39- 100%, with a 95% confidence interval of 91% - 100%.
Concordance of BE CERTAIN™ Home Pregnancy Test (Tested by End Table 6. User) Compared with E.P.T. Pregnancy Test (Tested by Professional User), Both Following a Urine Dip Method
| E.P.T.® (Prof. User) | ||||
|---|---|---|---|---|
| (+) | (-) | |||
| BE CERTAIN™(End User) | (+) | 61 | 0 | 61 |
| (-) | 1 | 38 | 39 | |
| Total | 62 | 38 | 100 |
Based on the above 2x2 analysis, the Concordance of the BE CERTAIN™ Home Pregnancy Test when tested by the End User, as compared with the predicate device, the
Natureplex, LLC IV- 5 BE CERTAIN™ Home Pregnancy Test 510(k) / Amendment No. 4 - 11/14/05)
{5}------------------------------------------------
E.P.T. ® Pregnancy Test as tested by the Professional User is 99/100= 99%, with a 95% confidence interval of 95% - 100%. The sensitivity of the BE CERTAIN™ Home Pregnancy Test is 61/62= 98.3%, with a 95% confidence interval of 91% - 100%. Finally, the Specificity of the BE CERTAIN™ Home Pregnancy Test is 38/38= 100%, with a 95% confidence interval of 91% - 100%.
The above studies show that the BE CERTAIN™ Home Pregnancy Test, when used by either an end user or a professional user following a urine dip method have a strong concordance. Likewise, the BE CERTAIN™ Home Pregnancy Test has a strong concordance with the predicate device, the E.P.T. ® Pregnancy Test.
COMPARISON STUDY USING THE URINE DROPSTREAM (2) METHOD
Spiked human urine samples from 50 normal, non-pregnant females were tested in order to determine the correlation of the new test, the BE CERTAIN™ Pregnancy Test, when used by subjects using a urine dropstream method, with that of the reference standard, the E.P.T. Pregnancy Test (i.e., the predicate device; previously cleared under 510(k) #K033658). The results of this study are as follows:
- Table 7. Concordance of BE CERTAIN™ Home Pregnancy Test (Tested by End User Using a Urine DropStream Method) Compared with E.P.T." Pregnancy Test (Tested by Professional User Using a Urine Dip Method)
| E.P.T.® (Urine Dip) | |||
|---|---|---|---|
| (+) | (-) | ||
| BE CERTAIN(Urine Stream) | 27 | 0 | 27 |
| (-) | 0 | 23 | 23 |
| Total | 27 | 23 | 50 |
Based on the above 2x2 analysis, the Concordance of the BE CERTAIN™ Home Pregnancy Test when tested by the End User using a urine dropstream method, as compared with the E.P.T.® Pregnancy Test (Tested by Professional User using a Urine Dip Method) is 50/50= 100%, with a 95% confidence interval of 93% - 100%. The sensitivity of the BE CERTAIN™ Home Pregnancy Test is 27/27= 100%, with a 95% confidence interval of 88% - 100%. Finally, the Specificity of the BE CERTAIN™ Home Pregnancy Test is 23/23= 100%, with a 95% confidence interval of 86% - 100%.
As expected, the BE CERTAIN™ Pregnancy Test, when tested using the urine dropstream method, had produced equivalent results with that of the dip urine method.
{6}------------------------------------------------
(1) OTHER INFORMATION [807.92(d)]
EXPECTED VALUES (1)
The BE CERTAIN™ Home Pregnancy Test is capable of detecting pregnancy by the first day of the missing period and no sooner.
CALIBRATION (2)
The BE CERTAIN™ Home Pregnancy Test is calibrated against the WHO 3rd International Standard for hCG.
QUALITY CONTROL (3)
The BE CERTAIN™ Home Pregnancy Test has built in Quality Control Features. After addition of the urine sample, these colored bands migrate along the membrane at the leading edge of the dye conjugate and are "removed" from the test strip completely.
When the test is complete, the end user will see a pink-purple colored band in the "C" area of the test strip on negative samples and a pink-purple colored band in the "T" and "C" area on positive samples. The appearance of the CONTROL ("C") band indicates that the test strip is performing properly and serves as a procedural internal control.
{7}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/7/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV 2 3 2005
Mr. Victor J. Santos President Natureplex, LLC. 3791 Air Park Street Memphis, TN 38118
Re: K051963
Trade/Device Name: BE CERTAIN Pregnancy Test Regulation Number: 21 CFR 862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX Dated: November 16, 2005 Received: November 17, 2005
Dear Mr. Santos:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{8}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Alberto G. A.
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{9}------------------------------------------------
Indications for Use
510 (k) Number: K051963
Device Name:
BE CERTAIN Pregnancy Test
"Indications for Use": The BE CERTAIN Pregnancy Test is intended for the qualitative The DD CERTIFIN : Fregioned level of human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy. It is for over-thecounter consumer use.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
x Over-The-Counter Use (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Page 1 of 1
signature
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K051963
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.